Hims & Hers Health, Inc. Overview
Industry: Household & Personal Products
Sector: Consumer Defensive
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California. Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescript Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Hims & Hers Health, Inc. into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $608.1M (+4% YoY). Net loss was -$92.1M (from $49.5M). Adjusted EBITDA was $44.3M.
Revenue
$608.1M
+4% YoY
Net loss
-$92.1M
from $49.5M
Adjusted EBITDA
$44.3M
reported
Free cash flow
$53M
reported
What changed
- Revenue +4% YoY to $608.1M.
- Capital return update: free cash flow $53M.
- Net loss was -$92.1M (from $49.5M).
Guidance / outlook
For the second quarter 2026, we expect: • Revenue of $680 million to $700 million. • Adjusted EBITDA of $35 million to $55 million, reflecting an Adjusted EBITDA margin of 5% to 8%. For the full year 2026, we expect: • Revenue of $2.8 billion to $3.0 billion. • Adjusted EBITDA of $275 million to $350 million, reflecting an Adjusted EBITDA margin of 10% to 12%. 2 Our second quarter and full year 2026 outlook excludes...
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 11, 2026
SEC filing
8-K
May 11, 2026
SEC filing
10-K
Feb 23, 2026
SEC filing
8-K
Feb 23, 2026
Earnings release
Earnings release
Feb 23, 2026
SEC filing
10-Q
Nov 03, 2025
SEC filing
8-K
Nov 03, 2025
Earnings release
Earnings release
Nov 03, 2025
SEC filing
10-Q
Aug 04, 2025
SEC filing
8-K
Aug 04, 2025
Earnings release
Earnings release
Aug 04, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
Headline from Yahoo Finance: FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight.
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder
Headline from Yahoo Finance: HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder.
Does FDA Peptide Shift and CAO Exit Reframe the Bull Case for Hims & Hers Health (HIMS)?
Headline from Yahoo Finance: Does FDA Peptide Shift and CAO Exit Reframe the Bull Case for Hims & Hers Health (HIMS)?
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short
Headline from Yahoo Finance: HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short.
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide?
Headline from Yahoo Finance: Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide?
Hims & Hers Stock Pops on FDA Panel’s Peptide Recommendation
Headline from Barron's: Hims & Hers Stock Pops on FDA Panel’s Peptide Recommendation.
Earnings Per Share
Score 4.00/5
Hims & Hers Health, Inc. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Hershey Co
Procter & Gamble Company
Grand Canyon Education Inc
In
Household & Personal Products industry
, Procter & Gamble Company
, Colgate-Palmolive Company
, Church & Dwight Company Inc
are companies with high ratings.
Return on Equity
Score 0.81/5
Hims & Hers Health, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Hershey Co
Procter & Gamble Company
Grand Canyon Education Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.92/5
Hims & Hers Health, Inc.
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Hershey Co
Procter & Gamble Company
Grand Canyon Education Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.99/5
Hims & Hers Health, Inc.
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Hershey Co
Procter & Gamble Company
Grand Canyon Education Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios